asthma On the last five years the leukotriene and prostaglandin programs have yielded two highly effective and innovative medicines: the leukotriene D4 receptor antagonist SINGULAIR® (montelukast sodium) for bronchial asthma in adults and children as young as six, and VIOXX® (rofecoxib), a selective COX-2 inhibitor for osteoarthritis and acute pain. Research is also continuing on other approaches to treatments for human bronchial asthma, and investigating possibilities for building new bone in the bone-thinning disease, osteoporosis. |asthma|research|health|biochemistry|